Literature DB >> 28676447

Profiling conserved biological pathways in Autosomal Dominant Polycystic Kidney Disorder (ADPKD) to elucidate key transcriptomic alterations regulating cystogenesis: A cross-species meta-analysis approach.

Shatakshee Chatterjee1, Srikant Prasad Verma2, Priyanka Pandey3.   

Abstract

PURPOSE: Initiation and progression of fluid filled cysts mark Autosomal Dominant Polycystic Kidney Disease (ADPKD). Thus, improved therapeutics targeting cystogenesis remains a constant challenge. Microarray studies in single ADPKD animal models species with limited sample sizes tend to provide scattered views on underlying ADPKD pathogenesis. Thus we aim to perform a cross species meta-analysis to profile conserved biological pathways that might be key targets for therapy.
METHODS: Nine ADPKD microarray datasets on rat, mice and human fulfilled our study criteria and were chosen. Intra-species combined analysis was performed after considering removal of batch effect. Significantly enriched GO biological processes and KEGG pathways were computed and their overlap was observed. For the conserved pathways, biological modules and gene regulatory networks were observed. Additionally, Gene Set Enrichment Analysis (GSEA) using Molecular Signature Database (MSigDB) was performed for genes found in conserved pathways.
RESULTS: We obtained 28 modules of significantly enriched GO processes and 5 major functional categories from significantly enriched KEGG pathways conserved in human, mice and rats that in turn suggest a global transcriptomic perturbation affecting cyst - formation, growth and progression. Significantly enriched pathways obtained from up-regulated genes such as Genomic instability, Protein localization in ER and Insulin Resistance were found to regulate cyst formation and growth whereas cyst progression due to increased cell adhesion and inflammation was suggested by perturbations in Angiogenesis, TGF-beta, CAMs, and Infection related pathways. Additionally, networks revealed shared genes among pathways e.g. SMAD2 and SMAD7 in Endocytosis and TGF-beta.
CONCLUSION: Our study suggests cyst formation and progression to be an outcome of interplay between a set of several key deregulated pathways. Thus, further translational research is warranted focusing on developing a combinatorial therapeutic approach for ADPKD redressal.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  ADPKD; Conserved; Enrichment; Meta-analysis; Microarray; Pathways

Mesh:

Substances:

Year:  2017        PMID: 28676447     DOI: 10.1016/j.gene.2017.06.059

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  5 in total

1.  Informatics-guided drug repurposing for Autosomal Dominant Polycystic Kidney Disease (ADPKD).

Authors:  Anna A Kiseleva; Erica A Golemis
Journal:  EBioMedicine       Date:  2020-01-22       Impact factor: 8.143

2.  A high throughput zebrafish chemical screen reveals ALK5 and non-canonical androgen signalling as modulators of the pkd2-/- phenotype.

Authors:  A Metzner; J D Griffiths; A J Streets; E Markham; T Philippou; F J M Van Eeden; A C M Ong
Journal:  Sci Rep       Date:  2020-01-09       Impact factor: 4.379

3.  Identification of housekeeping genes for microRNA expression analysis in kidney tissues of Pkd1 deficient mouse models.

Authors:  J J Muñoz; A C Anauate; A G Amaral; F M Ferreira; R Meca; M S Ormanji; M A Boim; L F Onuchic; I P Heilberg
Journal:  Sci Rep       Date:  2020-01-14       Impact factor: 4.379

Review 4.  Metabolic Reprogramming and Reconstruction: Integration of Experimental and Computational Studies to Set the Path Forward in ADPKD.

Authors:  Roberto Pagliarini; Christine Podrini
Journal:  Front Med (Lausanne)       Date:  2021-11-24

5.  Identification of ADPKD-Related Genes and Pathways in Cells Overexpressing PKD2.

Authors:  Zhe Zhang; Yanna Dang; Zizengceng Wang; Huanan Wang; Yuchun Pan; Jin He
Journal:  Genes (Basel)       Date:  2020-01-22       Impact factor: 4.096

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.